Category: 596114-50-0

On December 14, 2017, Mansour, Tarek Suhayl; Chafeev, Mikhail; Yudin, Mikhail; Gezentsvey, Yury; Nikitin, Aleksandr published a patent.COA of Formula: C7H9ClN2 The title of the patent was Preparation of compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119. And the patent contained the following:

There are provided benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide compounds of formula I, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, type 2 diabetes mellitus, and related metabolic disorders. Compounds of formula I wherein one of X1 and X2 is O and the other one is SO2; X3 is CH, CF and N; X4 is independently CH and N; A is (un)substituted piperazinyl, (un)substituted pyrrolidinyl, (un)substituted piperidinyl, etc.; and enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, are claimed. Example compound II was prepared by etherification of (1-tert-butylpiperidin-4-yl)methanol with 4-(3,3-dioxido-1,3-benzoxathiol-6-yl)-2-fluorophenol. The invention compounds were evaluated for their GPR119 agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 833 nM and 75 % of cAMP stimulation. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).COA of Formula: C7H9ClN2

The Article related to benzoxathiole oxide preparation gpr119 agonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.COA of Formula: C7H9ClN2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 10, 2017, Chen, Gang; Chrovian, Christa C.; Coate, Heather R.; Dvorak, Curt A.; Gelin, Christine F.; Hiscox, Afton; Letavic, Michael A.; Rech, Jason C.; Soyode-Johnson, Akinola; Stenne, Brice; Wall, Jessica L.; Zhang, Wei published a patent.Recommanded Product: 596114-50-0 The title of the patent was Preparation of substituted 1,2,3-triazoles as NR2B-selective NMDA modulators. And the patent contained the following:

The invention relates to substituted 1,2,3-triazoles of formula I as NR2B receptor ligands that may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity. Compounds of formula I, wherein Ar1 is substituted Ph, (un)substituted pyridyl, substituted thienyl; R1 is H, halo, Me; R2 is H and Me; Ar3 is (un)substituted pyridyl, (un)substituted pyridazinyl, (un)substituted pyrimidin-4-yl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by condensation of (1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol with 2-chloropyrimidine. The invention compounds were evaluated for their NR2B modulatory activities. From the assay, it was determined that compound II exhibited IC50 value of 0.049 μM. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Recommanded Product: 596114-50-0

The Article related to preparation substituted triazole nr2b selective nmda modulator, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Recommanded Product: 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 6, 2019, Chafeev, Mikhail published a patent.Product Details of 596114-50-0 The title of the patent was Preparation of compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and uses thereof as agonists of G protein-coupled receptor 119. And the patent contained the following:

The title compounds I [X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 = CH, CF, N; X4 = (independently) CH or N; X6, X61 and X62 = (independently) H, halo, alkyl, etc.; X7 and X71 = H, halo, alkyl, etc.; or both X7 and X71, together form a cycloalkyl or heterocycle; A = (un)substituted alkoxy, piperazinyl and pyrrolidinyl] or enantiomers, diastereomers, hydrates, solvates, or pharmaceutically acceptable salts of I, or prodrugs or complexes thereof, useful in treating diseases and conditions associated with GPR119 dysregulation, type 2 diabetes mellitus, and related metabolic disorders, were prepared E.g., a multi-step synthesis of II, starting from 1-tert-butylpiperidine-4-one and trimethylsilyldiazomethane, was described. The potency of exemplified compounds I as GPR119 receptor agonists was assessed (data given). Also provided are compositions comprising compounds I. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Product Details of 596114-50-0

The Article related to benzooxathiole oxide preparation gpr119 agonist antidiabetic, diabetes mellitus type 2 metabolic disorder benzooxathiole oxide preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Product Details of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 6, 2014, Bono, Ayako; Matsuda, Daisuke; Otake, Kenichi; Kakinuma, Hiroyuki; Kobashi, Yohei; Kawamura, Madoka; Shiozawa, Fumiyasu; Shimizu, Yuki; Kawabe, Kenichi; Hamada, Makoto published a patent.Computed Properties of 596114-50-0 The title of the patent was Hypoglycemic agents containing condensed heterocyclic compounds as GPR119 agonists. And the patent contained the following:

Hypoglycemic agents contain condensed heterocyclic compounds I [A = (un)substituted Ph or 5-6 membered heteroaryl; W = bond, O, NH, OCH2, CH2O; X = N, CR21; Y1 = N, CR22; Y2 = N, CR23; Y3 = N, CR24; R21-R24 = H, C1-6 alkyl; B = (un)substituted C2-6 alkyl, C3-8 cycloalkyl, (C3-8 cycloalkyl)C1-6 alkyl, (aryl)C1-6 alkyl, (saturated heterocyclyl)C1-6 alkyl, COOR31, 5-6 membered heteroaryl; R31 = C1-6 alkyl, C3-8 cycloalkyl, etc.] or their pharmaceutically acceptable salts as active ingredients and are useful for prevention and treatment of diabetes mellitus. Thus, tert-Bu 4-[5-[4-(methylsulfonyl)phenyl]-1H-indazol-1-yl]piperidine-1-carboxylate, prepared by several steps, promoted cellular cAMP production in human GPR119-expressing cells with ED50 of 31 nM. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Computed Properties of 596114-50-0

The Article related to condensed heterocycle preparation hypoglycemic gpr119 agonist antidiabetic, indazolylpiperidinecarboxylate preparation hypoglycemic gpr119 agonist antidiabetic, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Computed Properties of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 11, 2016, Claremon, David A.; Dong, Chengguo; Fan, Yi; Leftheris, Katerina; Lotesta, Stephen D.; Singh, Suresh B.; Tice, Colin M.; Zhao, Wei; Zheng, Yajun; Zhuang, Linghang published a patent.Electric Literature of 596114-50-0 The title of the patent was Preparation of piperazine derivatives as liver X receptor modulators. And the patent contained the following:

Provided are novel compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of formula I and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer’s disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. Title compounds I [Q = alkyl-OC(O), heteroaryl, aryl-alkyl-OC(O), etc.; R1 = alkyl, cycloalkyl, aryl-alkyl, etc.; R2 = H, halo, cyano, etc.; R3 = alkyl, halo-alkyl, cycloalkyl, etc.; R4 = H or alkyl], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by reaction of (R)-tert-Bu 2-isopropylpiperazine-1-carboxylate with [3-(methylsulfonyl)phenyl]boronic acid. Compounds of the invention were evaluated for their LXr α/β binding ad agonist activity, e.g., II showed Ki value of 1690 nM and 157 nM on LXRα and LXRβ, resp. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Electric Literature of 596114-50-0

The Article related to piperazine derivative preparation liver receptor lxr modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 15, 2022, Arns, Stephen Paul; Hsieh, Tom Han Hsiao; Shidmoossavee, Fahimeh S.; Tan, Jason Samuel; Yee, Leanna; Paquette, Jay John; Jaquith, James Brian; Osborne, Simon; Smiljanic-Hurley, Ela; Hamby, Callum; Smyth, Elliott; Ambler, Martin; Minchinton, Andrew I.; Kyle, Alastair H.; Baker, Jennifer H. E. published a patent.Recommanded Product: 596114-50-0 The title of the patent was Preparation of 7-morpholino-1,6-naphthyridin-5-yl derivatives and use thereof as DNA-PK inhibitors. And the patent contained the following:

The present disclosure provides compounds of formula I and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. Compounds of formula I wherein R1a is H and C1-6 alkyl; R1b is C1-6 alkyl, C3-8 cycloalkyl, 3-8 heterocycloalkyl, etc.; R2 is halo, cyano, C1-6 alkyl, etc.; R3 is H, halo, C1-6 alkyl and C1-6 haloalkyl; R4 is C1-6 alkyl and C1-6 haloalkyl; and their pharmaceutically acceptable salts, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their DNA-PK inhibitory activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Recommanded Product: 596114-50-0

The Article related to morpholino naphthyridinyl preparation dna protein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Recommanded Product: 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 12, 2003, Cadilla, Rodolfo; Henke, Brad Richard; Lambert, Millard H., III; Liu, Guangcheng Kevin; Smith, Jennifer Susan published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of phenoxyalkanoic acid derivatives as hPPAR activators for treatment of diabetes and cardiovascular diseases. And the patent contained the following:

Title compounds I [wherein R1 and R2 = independently H, F, CF3, or alkyl; or CR1R2 = cycloalkyl; R3 = (un)substituted heteroaryl; R4 and R5 = independently H, (perfluoro)alkyl, (perfluoro)alkoxy, halo, or CN; R6 = (un)substituted Ph or heteroaryl; R7 and R8 = independently H, F, CF3, or alkyl with the proviso that the C to which R7 and R8 are bonded is either meta or para to the depicted O; m and n = independently 1-2; or pharmaceutically acceptable salts, solvates, acid isosteres, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators (no data). For example, Me 2-[4-[2-[[2,4-bis(trifluoromethyl)benzyl]amino]ethyl]phenoxy]-2-methylpropanoate was coupled with 2-chloro-5-ethylpyrimidine using DIEA in toluene to give the tertiary amine (38%). Hydrolysis of the ester with NaOH provided II (48%). Methods for treating diseases or conditions associated with hPPARα, hPPARγ, or hPPARδ, such as diabetes and cardiovascular diseases, comprising administration of a therapeutically effective amount of I or a pharmaceutical composition comprising I are also disclosed (no data). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine

The Article related to phenoxyalkanoic acid preparation ppar activator antidiabetic cardiovascular agent, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 28, 2012, Bohno, Ayako; Matsuda, Daisuke; Otake, Norikazu; Kakinuma, Hiroyuki; Kobashi, Yohei; Kawamura, Madoka; Shiozawa, Fumiyasu; Kawabe, Kenichi; Iwata, Yuki; Hamada, Makoto published a patent.Name: 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of 4-piperidinyl-condensed heterocyclic compounds as GPR119 agonists. And the patent contained the following:

The title compounds represented by general formula [I; group A = each (un)substituted Ph or 5 or 6-membered heteroaryl; W = a single bond, O, NH, OCH2, or CH2O; X = a nitrogen atom or CR21; Y1 = a nitrogen atom or CR22; Y2 = a nitrogen atom or CR23; Y3 = a nitrogen atom or CR24; R21, R22, R23, R24 = a hydrogen atom or C1-6 alkyl; group B = C2-6 alkyl, C3-8 cycloalkyl, (C3-8 cycloalkyl)C1-6 alkyl, (aryl)C1-6 alkyl, (saturated heterocyclyl)C1-6 alkyl, CO2R31 (R31 = C1-6 alkyl, C3-8 cycloalkyl, aryl or saturated heterocyclyl), or 5 or 6-membered heteroaryl] or pharmaceutically permitted salts thereof are prepared These compounds including indazolylpiperidine, benzotriazolylpiperidine, pyrazolopyridinylpiperidine, and triazolopyridinylpiperidine compounds have an outstanding glucose-dependent insulinotropic polypeptide receptors (GPR119) agonist action. They are useful as blood-sugar lowering agents for the prevention and/or treatment of diabetes. Thus, a solution of 150 mg tert-Bu 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-1-yl]piperidine-1-carboxylate in 1.5 mL DMF was treated with 155 mg 4-(1H-Tetrazol-1-yl)phenyl trifluoromethanesulfonate, [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride and 525 μL 2 M aqueous Na2CO3 solution, stirred at 100° for 1.5 h, and concentrated under reduced pressure to give, after silica gel chromatog., 100 mg tert-Bu 4-(5-[4-(1H-tetrazol-1-yl)phenyl]-1H-indazol-1-yl)piperidine-1-carboxylate (II). II and 4-[3-[1-(5-Chloropyrimidin-2-yl)piperidin-4-yl]-3H-[1,2,3]triazolo[4,5-c]pyridin-6-yl]-N-ethyl-2,3-difluorobenzamide(III) in vitro promoted the cellular production of cAMP with ED50 of 13 and 2 nM, resp., in cells expressing human GPR119. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Name: 2-Chloro-5-isopropylpyrimidine

The Article related to diabetes prevention treatment piperidinyl condensed heterocyclic compound preparation, piperidinyl condensed heterocyclic compound preparation gpr119 agonist, indazolylpiperidine benzotriazolylpiperidine preparation gpr119 agonist, pyrazolopyridinylpiperidine triazolopyridinylpiperidine preparation gpr119 agonist and other aspects.Name: 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Fu, Suhong; Xiang, Wei; Chen, Jinying; Ma, Liang; Chen, Lijuan published an article in 2017, the title of the article was Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists.Application of 596114-50-0 And the article contains the following content:

Aryloxymethyl piperidinyl 1,2,4-oxadiazoles I [R = Boc, 5-R2-2-pyrimidinyl; R1 = 5-formyl-2-furanyl, 5-formyl-2-thienyl, 5-acetyl-2-thienyl, 4-MeOC6H4, 4-MeSO2C6H4, 1-cyclopropyl-3-pyrazolyl, 1-methyl-3-pyrazolyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-chloro-4-pyridinyl, 6-methoxy-3-pyridinyl, 6-fluoro-3-pyridinyl, 6-methyl-3-pyridinyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-oxazolyl, 4-(ethoxycarbonyl)-5-methyl-2-thiazolyl, 4-(ethoxycarbonyl)-2-thiazolyl, 2-ethyl-1,2,4-oxadiazol-5-yl; R2 = Et, i-Pr, EtO] were prepared as potential GPR119 agonists; agonism of GPR119 in human cells expressing GPR119, comparison to the pos. control GSK1292263, and their calculated lipophilicities were determined The prepared compounds showed acceptable agonistic effects at GPR119; I (R = Boc; R1 = 5-pyrimidinyl) was the most active GPR119 agonist tested with an EC50 value of 20.6 nM, comparable to that of the pos. control. The structure-activity relationship of the prepared 1,2,4-oxadiazole derivatives for GPR119 agonism was determined The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Application of 596114-50-0

The Article related to butoxycarbonylpiperidinyl pyrimidinylpiperidinyl aryloxymethyl oxadiazole preparation gpr119 agonism lipophilicity, structure butoxycarbonylpiperidinyl pyrimidinylpiperidinyl aryloxymethyl oxadiazole gpr119 agonism, gpcr, gpr119, sar study, agonistic activity, camp and other aspects.Application of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 5, 2015, Blinn, James Robert; Flick, Andrew Christopher; Wennerstaal, Goeran Mattias; Jones, Peter; Kaila, Neelu; Kiefer, James Richard, Jr.; Kurumbail, Ravi G.; Mente, Scot Richard; Meyers, Marvin Jay; Schnute, Mark Edward; Thorarensen, Atli; Xing, Li; Zamaratski, Edouard; Zapf, Christoph Wolfgang published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of N-heteroaryl amides as RORC2 inhibitors. And the patent contained the following:

The present invention provides compounds I-VII [Y = H, halo, CN, etc.; R1 = H, alkyl, hydroxyalkyl, haloalkyl; X = NHC(O)R2, NHC(O)NHR2, NHSO2R2, etc.; R2 = alkyl, cycloalkyl, aryl, etc.; W = N-substituted 4-piperidinyl, 3-piperidinyl, 3-pyrrolidinyl, 3-azetidinyl], pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds I-VII and pharmaceutical compositions Ninety-five compounds I-VII were prepared E.g., a multi-step synthesis of VIII, starting from 5-nitroindole and tert-Bu 4-oxopiperidine-1-carboxylate, was described. Exemplified compounds I were evaluated for RORC2 activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine

The Article related to heteroaryl amide preparation rorc2 inhibitor immune inflammatory disorder treatment, antiinflammatory immunomodulator antiarthritic antirheumatic heteroaryl amide preparation interleukin17 decrease, sulfonamide urea amide heteroaryl indolyl pyrrolopyridinyl preparation rorc2 inhibitor and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia